Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Non-Malignant Pain Clear all
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care Clinic

NCT03043378
View directory record Official record
Conditions
Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

NCT00225797
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
33
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

NCT00195728
View directory record Official record
Conditions
Moderate to Severe Chronic, Non-malignant Pain
Interventions
Hydrocodone/Acetaminophen on Extended Release
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
76
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Naldemedine

NCT01965652
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 22, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

NCT00036712
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

NCT04096391
View directory record Official record
Conditions
Chronic Nonmalignant Pain, Pain, Intractable, Pain, Chronic
Interventions
Flowonix Prometra® II Programmable Infusion System, Pain Medicine
Device · Drug
Lead sponsor
Evolve Restorative Center
Other
Eligibility
22 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Pain Program for Active Coping & Training

NCT02113592
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Interdisciplinary pain program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

NCT00366431
View directory record Official record
Conditions
Constipation
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

NCT00278824
View directory record Official record
Conditions
Pain
Interventions
Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

NCT00365898
View directory record Official record
Conditions
Chronic Non-Malignant Pain
Interventions
Hydromorphone Hydrochloride Extended-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
14
States / cities
Phoenix, Arizona • Clearwater, Florida • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Pain Program for Active Coping & Training

NCT01888146
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Interdisciplinary pain program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional

Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

NCT06183281
View directory record Official record
Conditions
Chronic Pain
Interventions
CBT, Mindfulness, and Movement
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

NCT00312195
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Buprenorphine transdermal patch, Placebo to match BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
21
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Phoenix, Arizona • Loma Linda, California • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

NCT00060021
View directory record Official record
Conditions
Cancer
Interventions
acupuncture therapy, management of therapy complications, pain therapy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.

NCT00347685
View directory record Official record
Conditions
Chronic Pain
Interventions
tramadol ER
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 22, 2026, 4:56 PM EDT